Glycorex Transplantation AB Stock

Equities

GTAB B

SE0000524530

Medical Equipment, Supplies & Distribution

End-of-day quote NORDIC GROWTH MARKET 06:00:00 2024-04-14 pm EDT 5-day change 1st Jan Change
0.842 SEK -0.94% Intraday chart for Glycorex Transplantation AB -3.44% -36.45%
Sales 2021 29.01M 2.67M Sales 2022 37.39M 3.45M Capitalization 303M 27.92M
Net income 2021 -12M -1.11M Net income 2022 -8M -738K EV / Sales 2021 22.5 x
Net cash position 2021 33.08M 3.05M Net cash position 2022 23.52M 2.17M EV / Sales 2022 7.47 x
P/E ratio 2021
-56.1 x
P/E ratio 2022
-35.3 x
Employees 23
Yield 2021 *
-
Yield 2022
-
Free-Float 95.58%
More Fundamentals * Assessed data
Dynamic Chart
Glycorex Transplantation AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Glycorex Transplantation AB Announces Collaboration with University Hospital in Toulouse CI
Glycorex Transplantation AB Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Glycorex Transplantation AB and Cardiotec Vascularis Ltda. Sign Partnership Agreement CI
Glycorex Transplantation AB (Publ.) Announces Appointment of Erik Melgaard Pedersen as Head of Sales, Effective April 1, 2022 CI
Glycorex Transplantation AB Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Glycorex Transplantation AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2021 CI
Glycorex Transplantation Announces Agreement with Distributor in South Africa CI
More news
1 day+2.41%
1 week+4.68%
1 month-4.28%
3 months-39.29%
6 months-51.01%
Current year-35.85%
More quotes
1 week
0.81
Extreme 0.81
0.85
1 month
0.80
Extreme 0.8
0.99
Current year
0.80
Extreme 0.8
1.44
1 year
0.80
Extreme 0.8
4.19
3 years
0.80
Extreme 0.8
13.02
5 years
0.80
Extreme 0.8
19.25
10 years
0.80
Extreme 0.8
19.25
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 21-12-31
Founder 71 95-12-31
Sales & Marketing - 22-03-31
Members of the board TitleAgeSince
Founder 71 95-12-31
Chairman 71 99-12-31
Director/Board Member 72 22-12-31
More insiders
Date Price Change Volume
24-04-15 0.842 -0.94% 32,819
24-04-12 0.85 +2.41% 85,999
24-04-11 0.83 +2.47% 14,800
24-04-10 0.81 -4.71% 107,819
24-04-09 0.85 -2.52% 22,594

End-of-day quote NORDIC GROWTH MARKET, April 11, 2024

More quotes
Glycorex Transplantation publ AB is a Sweden-based medical device company engaged in the research, development, production and sales of medical devices within the field of organ transplantation. The Company's main product, Glycosorb-ABO, facilitates organ transplantation between different blood types. Additionally, the Company has developed complementary product variants, such as Glycosorb-ABO A/B-kolonn, designed for different patient categories, and Glycosorb-Xeno, which can facilitate transplants between animals and humans. As of December 31, 2011, Glycosorb-ABO was used in 103 transplantation centers in 22 countries. As of December 31, 2011, the Company had four wholly owned subsidiaries, namely Glycoprobe AB, Glycorex Transplantation, Glycorex UMC AB and Glycorex UBP AB.
Calendar
More about the company
  1. Stock Market
  2. Equities
  3. GTAB B Stock